Solution to expedite CD12 patient enrollment: H
Post# of 153802
(Total Views: 539)
Posted On: 10/23/2020 11:02:23 AM
Solution to expedite CD12 patient enrollment:
Hearing there are still 63 more patients needed for this phase of CD12 study and the struggles Dr. Jay Lalazari mentioned on the CC, I've been thinking about how to expidite those trials.
I found this website:
https://www.clinicalconnection.com/44284.aspx
Hoping Cytodyn's done more research than me, I've only put in a few hours. But why not pay a company like this to fill the 63 patients?? Or at least a bunch of them. Why not pay 5 of these companies and just be done with it??
With other CCR5 antagonists out there, seems so clear its a race! Even though leronlimab probably has the best safety profile, we've seen FDA approve other drugs that cause liver problems (cough, cough remdesivir). What's to stop them from approving Maraviroc next. Pfizer started phase 3 trial in September and expects to be done in Dec with results in Jan.
Hoping they/we do all we can to get 63 more patients ASAP.
Can anyone reccommend this to Cytodyn that has a relationship wtih them? - I've emailed them to help them with their tech issues, no response.
I'm hoping we don't have a CC for a long time, great things are in motion with the hiring of the CSO and I'd rather not see them keep feeding the shorts opportunities, but if another CC is mentioned I'll be sure to type it into the question panel.
Thanks, Lee
Hearing there are still 63 more patients needed for this phase of CD12 study and the struggles Dr. Jay Lalazari mentioned on the CC, I've been thinking about how to expidite those trials.
I found this website:
https://www.clinicalconnection.com/44284.aspx
Hoping Cytodyn's done more research than me, I've only put in a few hours. But why not pay a company like this to fill the 63 patients?? Or at least a bunch of them. Why not pay 5 of these companies and just be done with it??
With other CCR5 antagonists out there, seems so clear its a race! Even though leronlimab probably has the best safety profile, we've seen FDA approve other drugs that cause liver problems (cough, cough remdesivir). What's to stop them from approving Maraviroc next. Pfizer started phase 3 trial in September and expects to be done in Dec with results in Jan.
Hoping they/we do all we can to get 63 more patients ASAP.
Can anyone reccommend this to Cytodyn that has a relationship wtih them? - I've emailed them to help them with their tech issues, no response.
I'm hoping we don't have a CC for a long time, great things are in motion with the hiring of the CSO and I'd rather not see them keep feeding the shorts opportunities, but if another CC is mentioned I'll be sure to type it into the question panel.
Thanks, Lee
(2)
(0)